Instituto de Investigación Biomédica de A Coruña (INIBIC)
Research center
Hospital Virgen de la Concha
Zamora, EspañaPublications in collaboration with researchers from Hospital Virgen de la Concha (12)
2023
-
ALERGODATA: Sentinel Registry of Health Outcomes in Allergic Patients Treated With Biological Therapies at Specialized Allergology Clinics in Spain
Journal of Investigational Allergology and Clinical Immunology, Vol. 33, Núm. 6, pp. 479-482
2022
-
Dolutegravir plus rilpivirine: benefits beyond viral suppression: DORIPEX retrospective study
Medicine (United States), Vol. 101, Núm. 24, pp. E29252
2020
-
The value of the continuous genotyping of multi-drug resistant tuberculosis over 20 years in Spain
Scientific Reports, Vol. 10, Núm. 1
2019
-
Diverse large HIV-1 non-subtype B clusters are spreading among men who have sex with men in Spain
Frontiers in Microbiology, Vol. 10, Núm. APR
-
Incidence of first cardiovascular event in Spanish patients with inflammatory rheumatic diseases: prospective data from the CARMA project
Clinical and experimental rheumatology, Vol. 37, Núm. 5, pp. 731-739
2018
2017
-
Lipoprotein(a) concentrations in rheumatoid arthritis on biologic therapy: Results from the CARdiovascular in rheuMAtology study project
Journal of Clinical Lipidology, Vol. 11, Núm. 3, pp. 749-756.e3
2016
-
Comprehensive clinical and epidemiological assessment of colonisation and infection due to carbapenemase-producing Enterobacteriaceae in Spain
Journal of Infection, Vol. 72, Núm. 2, pp. 152-160
-
Cut-offs and response criteria for the Hospital Universitario la Princesa Index (HUPI) and their comparison to widely-used indices of disease activity in rheumatoid arthritis
PLoS ONE, Vol. 11, Núm. 9
2008
-
Low rate of adverse hepatic events associated with fosamprenavir/ritonavir-based antiretroviral regimens
HIV Clinical Trials, Vol. 9, Núm. 5, pp. 309-313
-
Prevalence, risk factors, and impact of knee pain suggesting osteoarthritis in Spain
Clinical and Experimental Rheumatology, Vol. 26, Núm. 2, pp. 324-332
-
Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer
Journal of the National Cancer Institute, Vol. 100, Núm. 11, pp. 805-814